Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study (NCT07696832) | Guangdong Association of Clinical Trials | 2026-01-20 |
Track Patients Must Have Histologically or Cytologically Confirmed Locally Advanced or Metastatic NSCLC automatically
Every clearance here is in the API, with alerts when new ones post.